- Morning Sickness
- Drugs in Pregnancy
- Alcohol, Nicotine, Substance Use
- Folic Acid
- Breastfeeding & Drugs
- Cancer in Pregnancy
- HIV and HIV Treatment
- Conditions in Pregnancy
- Infectious Diseases in Pregnancy
- Occupational & Environmental Exposures
- Pharmacokinetics/ Drug Metabolism
- The ReproPsych Group
- CAS Newsletter
1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
2013 FACE meeting
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting .
- Read more in our News Archive
Current Studies at Motherisk
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
Cancer in Pregnancy: Mitoxantrone
Mitoxantrone (Novantrone) is 1,4-dihydroxy-5,8-bis ((2-((2-hydroxyethyl)amino)ethyl)amino)anthraquinone, often abbreviated DHAQ. It is an antineoplastic agent that appears to bind DNA and produce strand scission 1,2.
|In vitro studies||mammalian assay systems||Mitoxantrone is genotoxic in several mammalian assay systems 3-5.|
|Animal studies *||Rabbits||up to 0.4 mg/kg/day||We have been unable to locate references on possible developmental toxicity of mitoxantrone; however, ametantrone, a similar agent, was teratogenic in rabbits at doses of 0.4mg/kg/day but not at 0.2 mg/kg/day 6.|
|Rats||up to 6 mg/kg/day||Ametantrone was not teratogenic in rats at up to 6 mg/kg/day 6.|
|Human studies||Case reports||2nd trimester Combination with: cytarabine + idarubicin||Two case reports have described the use of mitroxantrone during the second trimester of human pregnancy 7,8. In one case, five weeks of therapy with mitroxantrone and cytarabine up to developmental week 28 were accompanied by normal fetal growth 7. Subsequent introduction of idarubicin to replace mitroxantrone was followed by death of the fetus. In the second case, a mother treated with a variety of chemotherapeutic agents including mitroxantrone from 24 to 34 weeks of gestation delivered a normal female infant 8.|
|Breast feeding||Pharmacokinetic||Mitoxantrone is excreted in breast milk in small amounts 8.|
|Case reports||Based on data from one lactating mother, this agent is apparently stored and released slowly into breast milk for at least one month after its administration 8. Although the quantities of drug in milk were very low (10-20 ng/mL), breastfeeding was not recommended in this case.|
- Alberts DS et al: Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3:101-7, 1985.
- Locher SE, Meyn RE: Relationship between cytotoxicity and DNA damage in mammalian cells treated with anthracenedione derivatives. Chem Biol Interact 46:369-79, 1983.
- Manandhar M et al: Genetic toxicology profile of the new antineoplastic drug mitoxantrone in the mammalian test systems. Arzneimittelforschung 36:1375-9, 1986.
- Au WW et al: Comparative structure-genotoxicity study of three aminoathraquinone drugs and doxorubicin. Cancer Res 41:376-9, 1981.
- Rosenberg LJ, Hittelman WN: Direct and indirect clastogenic activity of anthracenedione in Chinese hamster ovary cells. Cancer Res 43:3270-5,1983.
- Petrere JA et al: Teratology studies of ametantrone acetate in rats and rabbits. Teratology 34:271-8, 1986.
- Reynoso EE, Huerta F: Acute leukemia and pregnancy - fatal fetal outcome after exposure to idarubicin during the second trimester. ActaOncologica 33:703-16, 1994.
- Azuno Y, Kaku K, Fujita N: Mitoxantrone and etoposide in breast milk. Am J Hematol 48:131-2, 1995.